Which whooping cough vaccine and at which age?;Quel vaccin coquelucheux et à quel âge?

Medecine Therapeutique Pediatrie

Volumn 9, Issue 3, 2006, Pages 160-169

  Gaudelus, Joël ^a   Guiso, Nicole ^b   Cohen, Robert ^c  

^a HÔPITAL JEAN VERDIER   (France)

^b INSTITUT PASTEUR   (France)

^c HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BOOSTRIX TETRA; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; PENTACOQ; PERTUSSIS VACCINE; UNCLASSIFIED DRUG;

CELLULAR IMMUNITY; HEALTH SURVEY; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; NONHUMAN; PERTUSSIS; REVIEW; VACCINATION;

EID: 33749576568     PISSN: 12865494     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Hoag WB. General considerations concerning pertussis, with special emphasis on vaccine therapy - prophylatic and curative. Am Med 1916: 255-65; (April).
2. Masden T. Vaccintation against whooping cough. JAMA 1933; 101: 187-8.
3. Kendrick PL, Eldering G, Dixon MK, Misner J. Mouse protection tests in the study of pertussis vaccine. Am J Public Health 1947; 37(7): 803-10.
4. Council M. Vaccination against whooping cough. The final report to the Immunization Committee of the Medical Research Council and to the Medical Officers of Health for Battersea and Wandsworth. Bradford, Liverpool and Newcastle. BMJ 1959; 1: 994-1000.
5. Preston N. Type-specific immunity vaccine, a little cause for concern. Lancet 1965; 1: 1065-7.
6. Njamkepo E, Rimlinger F, Thiberge S, Guiso N. Thirty-five years' experience with the whole-cell pertussis vaccine in France: vaccine strains analysis and immunogenicity. Vaccine 2002; 20(9-10): 1290-4.
7. Trollfors B. Bordetella pertussis whole-cell vaccine. Efficacy and toxicity. Acta Pediatr Scand 1984; 73: 417-25.
8. Messiah A, Flahault A. Enquête: absence de liaison entre la vaccination tétravalente et le syndrome de mort subite du nourrisson. BEH 1986; 52: 205-6.
9. Griffin MR, Ray WA, Mortimer EA, Fenichel GM, Schaffner W. Risk of seizures and encephalopathy after immunization with the diphtheria-tetanus- pertussis vaccine. JAMA 1990; 263(12): 1641-5; [see comments].
10. Gale JL, Thapa PB, Wassilak SG, Bobo IK, Mendelman PM, Foy HM. Risk of serious acute neurological illness after immunization with diphtheria-tetanus- pertussis vaccine. A population-based case-control study. JAMA 1994; 271(1): 37-41; [see comments].
11. Stetler H, Orenstein W, Bart K, Brink E, Brennan J, Hinman A. History of convulsions and use of pertussis vaccine. J Pediatr 1985; 107: 175-9.
12. Cody CL, Baraff LJ, Cherry JD, Marcy SM, Manclark CR. Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics 1981; 68(5): 650-60.
13. Thomas MG, Ashworth LA, Miller E, Lambert HP. Serum IgG, IgA, and IgM responses to pertussis toxin, filamentous hemagglutinin, and agglutinogens 2 and 3 after infection with Bordetella pertussis and immunization with whole-cell pertussis vaccine. J Infect Dis 1989; 160(5): 838-45.
14. Guiso N, Grimprel E, Anjak I, Begue P. Western blot analysis of antibody responses of young infants to pertussis infection. Eur J Clin Microbiol Infect Dis 1993; 12(8): 596-600.
15. Englund JA, Decker MD, Edwards KM, Pichichero ME, Steinhoff MC, Anderson EL. Acellular and whole-cell pertussis vaccines as booster doses: a multicenter study. Pediatrics 1994; 93(1): 37-43.
16. Edwards K, Decker MD. Pertussis vaccine. In MSD AP. In: Vaccines. Plotkin: Orenstein: Elsevier Inc., 4th Ed, 2004: 471-528.
17. Grimprel E, Begue P, Anjak I, Njamkepo E, Francois P, Guiso N. Long-term human serum antibody responses after immunization with whole-cell pertussis vaccine in France. Clinic Diagnost Lab Immunol 1996; 3(1): 93-7.
18. Guiso N, Njamkepo E, Vie le Sage F, et al. Long-term humoral and cell-mediated immunity after acellular pertussis vaccination compares favourably with whole-cell vaccines six years after booster vaccination in the second year of life, (soumis).
19. Ausiello CM, Lande R, la Sala A, Urbani F, Cassone A. Cell-mediated immune response of healthy adults to Bordetella pertussis vaccine antigens. J Infect Dis 1998; 178(2): 466-70.
20. Wirsing von Konig CH, Halperin S, Riffelmann M, Guiso N. Pertussis of adults and infants. Lancet Infect Dis 2002; 2(12): 744-50.
21. Gustafsson L, Hallander H, Olin P, Reiozenstein E, Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996; 334: 349-55.
22. Greco D, Salmaso S, Mastrantonio P, et al. A controlled trial of two accelular vaccines and one whole-cell vaccine against pertussis. N Engl J Med 1996; 334: 341-8.
23. Baron S, Njamkepo E, Grimprel E, et al. Epidemiology of pertussis in French hospitals in 1993 and 1994: thirty years after a routine use of vaccination. Pediat Inf Dis J 1998; 17(5): 412-8.
24. Guiso N, Capiau C, Carletti G, Poolman J, Hausser P. Intranasal murine model of Bordetella pertussis infection. I. Prediction of protection in human infants by acellular vaccines. Vaccine 1999; 17: 2366-76.
25. Anonymous. http://www.invs.sante.fr/recherche/index2.asp?txtQuery= renacoq.
26. Simondon F, Preziosi MP, Yam A, et al. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine 1997; 15(15): 1606-12.
27. Decker MD, Edwards KM, Steinhoff MC, et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics 1995; 96(3 Pt 2): 557-66.
28. Mallet E, Matisse N, Mathieu N, Langue J, Boisnard F, Soubeyrand B. Antibody persistence against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b (Hib) in 5-6-year-old children after primary vaccination and first booster with a pentavalent combined acellular pertussis vaccine: immunogenicity and tolerance of a tetravalent combined acellular pertussis vaccine given as a second booster. Vaccine 2004; 22(11-12): 1415-22.
29. Grimprel E, von Sonnenburg F, Sanger R, Abitbol V, Wolter JM, Schuerman LM. Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults. Vaccine 2005; 23(28): 3657-67.
30. Ausiello C, Urbani F, La Sala A, Lande R, Cassone A. Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infect Immun 1997: 2168-74.
31. Cherry JD, Gornbein J, Heininger U, Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 1998; 16(20): 1901-6.
32. Storsaeter J, Hallander HO, Gustafsson L, Olin P. Levels of antipertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 1998; 16(20): 1907-16.
33. Ward JI, Cherry JD, Chang SJ, et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med 2005; 353(15): 1555-63.
34. Boursaux-Eude C, Thiberge G, Carletti G, Guiso N. Intranasal murine model of Bordetella pertussis infection: II. Sequence variation and protection induced by a tricomponent acellular vaccine. Vaccine 1999; 17: 2651-60.
35. Anonymous. Calendrier Vaccinal 2005. Bull Epidemiol Heb 2005; 29-30: 141-56.
36. Gilberg S, Njamkepo E, Du Chatelet IP, et al. Evidence of Bordetella pertussis Infection in Adults Presenting with Persistent Cough in a French Area with Very High Whole-Cell Vaccine Coverage. J Infect Dis 2002; 186(3): 415-8.
37. Bassinet L, Matrat M, Njamkepo E, Aberrane S, Housset B, Guiso N. Nosocomial pertussis outbreak among adult patients and healthcare workers. Infect Control Hosp Epidemiol 2004; 25(11): 995-7.
38. ACIP Votes to Recommend Use of Combined Tetanus DaPT. Vaccine for Adults 2006; Accessed April 5, 2006 at http://www.cdc.gov/nip/vaccine/tdap/ tdap_adult_recs.pdf.
39. Heininger U, Cherry JD, Stehr K, et al. Comparative Efficacy of the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine and Lederle whole-cell component DTP vaccine in German children after household exposure. Pertussis Vaccine Study Group. Pediatrics 1998; 102(3 Pt 1): 546-53.
40. Olin P, Rasmussen F, Gustafsson L, Hallander HO, Heijbel H. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet 1997; 350(9091): 1569-77;
41. [see comments published erratum appears in Lancet 1998 7; 351(9100): 454].
42. Bégué P, Stagnara J. Vie le Sage F, Bernard J, Xerri B, Abitbol V. lmmunogenicity and reactogenicity of a booster dose of diphteria, tetanus, acellular pertussis and inactived poliomyelitis vaccines given concurrently with Haemophilus type b conjugate vaccine or as pentavalent vaccine. Pediat Inf Dis J 1997; 16: 787-94.
43. Bégué P, Grimprel E, Giovannangeli M, Abitbol V. Comparative reactogenicity and immunogenicity of booster doses of diphteria-tetanus-acellular-inactived poliovirus vaccine and diphteria-tetanus-inactived poliovirus vaccine in preadolescents. Pediat Inf Dis J 1998; 17: 804-9.
44. Weber C, Boursaux-Eude C, Coralie G, Caro V, Guiso N. Polymorphism of Bordetella pertussis isolates circulating the last ten years in France, where a single effective whole-cell vaccine has been used for more than thirty years. J Clin Microbiol 2001; 39(12): 4396-403.
45. Caro V, Njamkepo E, Van Amersfoorth SC, et al. Pulsed-field gel electrophoresis analysis of Bordetella pertussis populations in various European countries with different vaccine policies. Microbes Infect 2005; 7(7-8): 976-82.
46. Caro V, Hot D, Guigon G, et al. Temporal analysis of French Bordetella pertussis isolates by comparative whole-genome hybridization. Microb Infect [date]; (sous presse).
47. Guiso N, Levy C, de La Rocque F, et al. Observatoire National de la Coqueluche en Pédiatrie Ambulatoire. RICAI 2003; (Abstract n° 169).
48. Eskola J. Analysis of Haemophilus influenzae type B conjugate and diphtheria-tetanus-pertussis combination vaccines. J Infect Dis 1996; 174(Suppl 3): S302-S305.
49. Trollfors B, Taranger J, Lagergärd T, et al. A placebo-controlled trial of a pertussis-toxoid vaccine. N Engl J Med 1995; 333: 1045-50.
50. Liese J, Meschievitz C, Harzer E, et al. Efficacy of a two-component acellular pertussis vaccine in infants. Pediatr Inf Dis J 2000; 20: 1038-44.